MET and neoplasm: Savolitinib, a MET inhibitor, was reported to induce tumor regressions in PRCC patient-derived xenograft models [9], and a phase II clinical trial to evaluate its efficacy in PRCC patients was recently launched (ClinicalTrials.gov.